Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
Company Details
- Employees
- 382
- Founded
- -
- Address
- 989 E Hillsdale Blvd.,
- Phone
- 650-667-4085
- in****@****rma.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mirumpharma.com
- Keywords
- director at FRAXA.
- HQ
- Foster City, CA
Mirum Pharmaceuticals, Inc. Questions
Mirum Pharmaceuticals, Inc.'s helpline number is 650-667-4085
Mirum Pharmaceuticals, Inc.'s website is mirumpharma.com
Mirum Pharmaceuticals, Inc.'s LinkedIn profile is https://www.linkedin.com/company/mirum-pharmaceuticals
Mirum Pharmaceuticals, Inc. has
382 employees.
View email and phone details for 382
employees at Mirum Pharmaceuticals, Inc..
Mirum Pharmaceuticals, Inc.'s industry is
Pharmaceutical Manufacturing
Mirum Pharmaceuticals, Inc.'s top competitors are
Summit Therapeutics, Inc.,
Ionis Pharmaceuticals, Inc.,
Bridgebio,
Madrigal Pharmaceuticals,
Revolution Medicines,
Alnylam Pharmaceuticals,
Allogene Therapeutics,
Vera Therapeutics, Inc.,
Denali Therapeutics,
Corcept Therapeutics.
Mirum Pharmaceuticals, Inc.'s support email address is info@mirumpharma.com
Mirum Pharmaceuticals, Inc.'s categories are Pharmaceutical Manufacturing
Mirum Pharmaceuticals, Inc.'s founding year is 2018
